Human Genome Sciences Newswire

Human Genome Sciences Newswire

Comprehensive Real-Time News Feed for Human Genome Sciences.

Results 1 - 13 of 13 in Human Genome Sciences

  1. Bubble Stocks Top The Takeover Premium ChartsRead the original story w/Photo

    Sep 23, 2016 | Seeking Alpha

    ... the top 10 in eleventh place. Interestingly, however, despite huge activity in the cancer space, only Human Genome Sciences can be loosely described as an oncology target. This analysis also illustrates that these big premiums are far from just the ...

    Comment?

  2. More informationRead the original story

    Sep 17, 2016 | Austin Monthly

    ... solutions to complex business problems. Mr. Walfish was Senior Manager Biostatistics, Nonclinical at Human Genome Sciences in Rockville MD. Mr. Walfish has held positions with PricewaterhouseCoopers, Chiron Diagnostics and Johnson & Johnson. Mr. ...

    Comment?

  3. More informationRead the original story

    Sep 17, 2016 | Austin Monthly

    ... Statistical Outsourcing Services, Mr. Walfish was the Senior Manager Biostatistics, Non-clinical at Human Genome Sciences in Rockville MD. Prior to joining HGS, Mr. Walfish was a Senior Associate at PricewaterhouseCoopers specializing in the ...

    Comment?

  4. GlobalCompliancePanel Announces In-Person Seminar on, "Statistics for ...Read the original story w/Photo

    Aug 14, 2016 | 24-7 Press Release

    ... Statistical Outsourcing Services, Mr. Walfish was the Senior Manager, Biostatistics (Non-clinical) at Human Genome Sciences in Rockville MD. Satisha Naraharimurthy , Founder and CEO of NetZealous LLC , said that his company seeks to be at the ...

    Comment?

  5. Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical OfficerRead the original story w/Photo

    Jul 12, 2016 | PR Newswire

    ... member, or director of more than a dozen biopharmaceutical companies, including ProScript, Millennium, Human Genome Sciences, and Radius Pharmaceuticals. He currently serves on the Board of Directors of the Flagship company Rubius Therapeutics. Dr. ...

    Comment?

  6. Human Genome Sciences Opens Manufacturing and Process Development PlantRead the original story

    Dec 31, 1995 | Pharmaceutical Online

    Last month, Human Genome Sciences Inc. opened a new 80,000 square foot, $42 million manufacturing and process development plant, believed to be the first facility in the world designed to manufacture drugs resulting from genomics R&D. At the opening ceremony, William A. Haseltine, Chairman and CEO of HGS, said, "As the world's genomics pioneer, we were the first to achieve two important industry milestones.

    Comment?

  7. New Genetic Research Can Significantly Improve Drug DevelopmentRead the original story

    Jun 16, 2016 | P&T Community

    ... so inhibiting Lp-PLA2 might be beneficial. Darapladib, an inhibitor of Lp-PLA2, was developed by Human Genome Sciences, which GlaxoSmithKline (GSK) bought for $3 billion in 2012. But two large phase 3 trials of darapladib funded by GSK were ...

    Comment?

  8. Prospective biobank studies with genetic data can help improve drug development, reduce costsRead the original story w/Photo

    Jun 15, 2016 | Medical News

    ... so inhibiting Lp-PLA2 might be beneficial. Darapladib, an inhibitor of Lp-PLA2, was developed by Human Genome Sciences which GlaxoSmithKline (GSK) bought for US$ 3 billion in 2012. But two large phase III trials of darapladib funded by GSK were ...

    Comment?

  9. FDAnews Announces - Choosing the Best Device Sample Size for...Read the original story w/Photo

    May 23, 2016 | PRWeb

    ... starting Statistical Outsourcing Services, he was the Senior Manager Biostatistics, Non-clinical, at Human Genome Sciences in Rockville, MD. Prior to joining HGS, he was a senior associate at PricewaterhouseCoopers specializing in the pharmaceutical ...

    Comment?

  10. AbSci Appoints To Board Of DirectorsRead the original story

    May 15, 2016 | BioSpace

    ... from 2007 to 2010. Prior to Sutro, Dr. Gold was Senior Vice President of Pharmaceutical Operations at Human Genome Sciences from 2002 to 2006 and served as Vice President and CSO at Covance Biotechnology Services from 1996 to 2002. Earlier in his ...

    Comment?

  11. Valeant Seeks Fresh Start with Board ShakeupRead the original story

    May 1, 2016 | BioSpace

    ... also served as a member of the boards of directors of SkyePharma, plc from May 2001 to May 2009 and Human Genome Sciences from 2003 to 2013. Mr. Robertson has served as Executive Vice President and Head, Anti-Money Laundering, at BMO Financial Group ...

    Comment?

  12. Valeant gutted its board less than 24 hours ago and already has some new nominees to refill itRead the original story w/Photo

    Apr 29, 2016 | Silicon Alley Insider

    ... also served as a member of the boards of directors of SkyePharma, plc from May 2001 to May 2009 and Human Genome Sciences from 2003 to 2013. Mr. Robertson has served as Executive Vice President and Head, Anti-Money Laundering, at BMO Financial Group ...

    Comment?

  13. DNA Guru Trades the 86th Floor of Trump for Fifth AvenueRead the original story

    Feb 12, 2016 | The New York Observer

    ... it's definitely not pocket change, it's not quite what Dr. Haseltine, the former Chairman and CEO of Human Genome Sciences, had in mind when he first listed the place for $19.5 million last June with Town Residential broker Debra Stotts . Perhaps ...

    Comment?